## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### **SCHEDULE 14A**

# INFORMATION REQUIRED IN PROXY STATEMENT

# SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Filed by a		trant □ ther than the Registrant ⊠	
Check the	approp	riate box:	
	Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12		
		Enzo Biochem, Inc.	
		(Name of Registrant as Specified In Its Charter)  ROUMELL ASSET MANAGEMENT, LLC  MATTHEW M. LOAR  JAMES C. ROUMELL  EDWARD TERINO  (Name Of Person(s) Filing Proxy Statement, If Other Than The Registrant)	
Dorum out	e Eilin o		
Payment (		Fee (Check the appropriate box):	
		of fee required	
	Fee c	omputed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11	
	(1)	Title of each class of securities to which transaction applies:	
	(2)	Aggregate number of securities to which transaction applies:	
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):	
	(4)	Proposed maximum aggregate value of transaction:	
	(5)	Total fee paid:	
	Fee p	Fee paid previously with preliminary materials.	
		k box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify revious filing by registration statement number, or the Form or Schedule and the date of its filing.	
	(1)	Amount Previously Paid:	
	(2)	Form, Schedule or Registration Statement No.:	
	(3)	Filing Party:	
	(4)	Date Filed:	

Roumell Asset Management, LLC, together with the other participants named herein (collectively, "RAM"), intends to file a preliminary proxy statement and accompanying proxy card with the Securities and Exchange Commission (the "SEC"), to be used to solicit votes for the election of its two highly-qualified director nominees at the 2020 annual meeting of shareholders (including any other meeting of shareholders held in lieu thereof, and adjournments, postponements, reschedulings or continuations thereof, the "Annual Meeting") of Enzo Biochem, Inc., a New York corporation (the "Company"), and for the approval of two business proposals to be presented at the Annual Meeting.

On December 2, 2020, the Company announced that it is conducting a conference call today at 4:30 p.m. Eastern Time with analysts and investors to discuss the Company's first quarter 2021 earnings. RAM believes analysts and investors in the Company should want answers to some critical questions during the conference call. RAM encourages the Company's management to proactively address these questions during the call, or, failing that, for analysts and investors to ask management these questions during the time allotted for questions and answers:

- Why doesn't the Company believe that accepting RAM's notice of its intent to submit nominations and proposals in connection with the upcoming Annual Meeting, which was submitted nearly two weeks ago, is in the best interest of shareholders?
- Why is it fair for the Company to unilaterally appoint two new directors (to replace shareholder-nominated directors) after October 6, 2020 (the date retrospectively set as the last date that shareholders could submit nominations based on the date of the Annual Meeting confirmed in the Company's "definitive" proxy statement) but then not provide shareholders an opportunity to nominate candidates to replace these appointed directors?
- Why did Elazar Rabbani and Barry W. Weiner receive bonuses from federal Paycheck Protection Program funds? And why has the Company failed to tie bonuses to specific performance metrics, despite having received shareholder feedback to the contrary on this very topic?
- Why is the Company spending shareholders' capital on suing its largest shareholder, after having already spent \$4.1 million in fiscal year 2020 to unsuccessfully defend against such shareholder in a proxy fight? What long-term shareholder interest does this litigation serve?

#### CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

RAM STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO RAM.

The participants in the proxy solicitation are Roumell Asset Management, LLC, Matthew M. Loar, James C. Roumell and Edward Terino (collectively, the "Participants").

As of the date hereof, Roumell Asset Management, LLC beneficially owns 2,769,479 shares of common stock, \$0.01 par value per share (the "Common Stock") of the Company. Mr. Roumell, as the President of Roumell Asset Management, LLC, may be deemed the beneficial owner of the 2,769,479 shares of Common Stock beneficially owned by Roumell Asset Management, LLC. As of the date hereof, none of Messrs. Loar or Terino own any shares of Common Stock.